Alan Heinrich’s practice focuses on intellectual property litigation. He has extensive experience litigating patents in the fields of biotechnology, medical devices and high tech. He has been a member of trial teams that have obtained multi-hundred million-dollar judgments on behalf of patent owners and have also successfully defended against multi-hundred million-dollar damages claims on behalf of accused infringers.

Alan previously served on Irell & Manella LLP’s Executive Committee and as chair of the firm's Hiring Committee. He is an adjunct faculty member at the University of California, Los Angeles, where he teaches Patent Intensive, an advanced patent law seminar, and has also taught Patent Law and Federal Courts at Loyola Law School.

Experience

  • Advanced Accelerator Applications USA Inc. v. Curium U.S. LLC (D. Del). Co-lead trial counsel for Curium in the first Hatch Waxman trial involving a radioligand therapy, which uses a radioisotope connected to a cell-binding peptide to deliver radiation directly to a tumor site. The case centered on patents covering Novartis’s Lutathera drug product, the first approved radioligand therapeutic, which has generated over $4.5B in sales revenues. Following a bench trial in December 2025, the court issued a complete win for Curium, ruling that Curium did not infringe any asserted claim and that all asserted claims were invalid.
  • VLSI Technology LLC v. Intel Corporation (W.D. Tex). Co-lead trial counsel for VLSI Technology LLC in a patent infringement lawsuit against Intel Corporation. The lawsuit involves two patents that improve the speed and performance of microprocessors. In March 2021, a jury found that Intel infringed the patents in suit, rejected Intel’s invalidity defense, and awarded $2.18 billion in reasonable royalty damages. In April 2022, a judge issued a $2.3 billion final judgment in the case. Alan was recognized as an Am Law "Litigator of the Week" for his role in the case.
  • VLSI Technology LLC v. Intel Corporation (W.D. Tex). Co-lead trial counsel for VLSI Technology LLC in separate patent infringement lawsuit against Intel Corporation. The lawsuit involves a patent on improved memory access requests that increase the performance of microprocessors. In November 2022, an Austin, Texas jury found that Intel infringed the patent in suit, rejected Intel’s invalidity defense, and awarded over $948 million in reasonable royalty damages, the exact sum requested by VLSI.
  • Alector v. Asa Abeliovich, M.D., Ph.D. (JAMS arbitration). Co-lead trial counsel for Dr. Asa Abeliovich, M.D., Ph.D. in a JAMS arbitration proceeding brought by Alector Inc. Dr. Abeliovich is the founder and CEO of Prevail Therapeutics, a clinical stage biotechnology company developing gene therapies for neurodegenerative diseases, including Parkinson’s and Frontotemporal Dementia. He is also the co-founder and a former consultant for Alector. In June 2019, Alector filed an arbitration against Dr. Abeliovich, claiming that he misappropriated Alector’s trade secrets in developing Prevail’s gene therapies. Alector sought a substantial monetary award as well as sweeping ownership rights to Prevail’s intellection property estate. After a two-week arbitration trial in July 2020, the arbitrator rejected all of Alector’s principal claims against Dr. Abeliovich, including allegations of misappropriation of trade secrets. Specifically, the arbitrator rejected Alector’s claims that Dr. Abeliovich used Alector trade secrets or confidential information in connection with his work on behalf of Prevail, as well as Alector’s claim that it had any rights to Prevail’s intellectual property.
  • Koninklijke Philips N.V. et al. v. ZOLL Medical Corp. (D. Mass.). Represented ZOLL Medical Corp. in a patent infringement lawsuit brought by its competitor Philips relating to external defibrillator technology. Irell took over the case from other counsel in 2014 after a loss at the liability phase. Philips initially sought over $900 million in damages. After Irell succeeded in knocking out some claims on appeal of the liability judgment, Philips reduced its damages claim to $217 million. In August 2017, a jury returned a verdict in which it rejected Philips’s claim for lost profits damages, found that ZOLL did not willfully infringe and awarded Philips a net of $7.1 million in damages, less than four percent of Philips’s claimed damages.
  • Personalis, Inc. v. Foresight Diagnostics (D. Colo.) Lead counsel for Foresight Diagnostics, at the time a Series A startup developing an innovative technology called PhasED-Seq, which allows for ultra-sensitive “liquid biopsies” to detect minimum residual disease in patients recovering from cancer. After Foresight was sued by its publicly traded competitor Personalis, the Irell team challenged all asserted patents in inter partes review (IPR) proceedings and obtained a rare pre-institution stay of the litigation. The case settled favorably for Foresight after the Patent Trial and Appeal Board (PTAB) instituted review on all five asserted patents and issued its final written decisions on the first two IPRs, invalidating every claim (42 claims in total) in those patents.
  • Kite Pharma v. Sloan Kettering Institute for Cancer Research (PTAB). Represented Sloan Kettering and Juno Therapeutics in an inter partes review (IPR) proceeding before the Patent Trial and Appeal Board (PTAB). Juno’s competitor Kite sought to invalidate all claims of U.S. Patent No. 7,446,190. The PTAB upheld the validity of all claims of the patent in a final written decision, which the U.S. Court of Appeals for the Federal Circuit summarily affirmed in June 2018.
  • Alnylam Pharmaceuticals, et al. v. Whitehead Institute for Biomedical Research, et al (D. Mass.). Represented Alnylam and the Max Planck Institute in a complex patent dispute concerning rights to fundamental technology covered in two families of patent applications in the field of RNA interference (gene silencing). The case was successfully resolved on favorable terms through a creative settlement that used co-ownership rights and other cooperative mechanisms to overcome U.S. Patent and Trademark Office (USPTO) rejections in both patent application families, leading to a robust estate of issued patents.
  • University of Utah v. Alnylam Pharmaceuticals, et al. (D. Mass.). Represented Alnylam, Max Planck Institute, Whitehead and Massachusetts Institute of Technology in a dispute over inventorship rights to fundamental patents in the RNA interference (gene silencing) field co-owned by the defendants. In this case, Irell represented all of the parties involved in the lawsuit listed above, including parties who were adverse to Alnylam and Max Planck Institute in that lawsuit. The district court granted summary judgment against the University of Utah and in favor of the defendants on all claims. University of Utah did not appeal the district court's ruling.
  • University of Pennsylvania, et al. vs. St. Jude Children’s Research Hospital, et al. (E.D. Pa.). Represented Juno Therapeutics in a lawsuit against the University of Pennsylvania and Novartis Corporation. The lawsuit involved patent and contract claims concerning a novel cancer immunotherapy treatment developed by St. Jude Children’s Research Hospital and exclusively licensed to Juno. The treatment uses a “chimeric antigen receptor” that re-programs a patient’s own immune cells to identify and destroy cancerous B cells to treat diseases such as leukemia and lymphoma. The case settled favorably after several years of litigation, with Juno receiving upfront and milestone payments from Novartis as well as ongoing royalties.
  • Wisconsin Alumni Research Foundation v. Intel Corp. (W.D. Wis.). Represented WARF in litigation against Intel. WARF alleged that Intel's flagship Core Microarchitecture infringed a patent that arose from research at the University of Wisconsin, Madison. Three days before trial, Intel and WARF settled the case for a $110 million payment to WARF.
  • St. Jude Medical v. Access Closure, Inc. (W.D. Ark.). Represented St. Jude Medical in a patent case alleging infringement of St. Jude's patents relating to vascular closure devices. In December 2010, the jury returned a verdict of willful patent infringement and awarded St. Jude $27.1 million in damages, reportedly the largest jury verdict in any area of law in the U.S. District Court for the Western District of Arkansas. The U.S. Court of Appeals for the Federal Circuit affirmed the damages judgment on appeal.
  • Unwired Planet (f/k/a Openwave Systems) v. BlackBerry (ITC and D. Del.). Represented BlackBerry in patent litigation regarding mobile internet technology. Unwired Planet initially instituted proceedings in the U.S. International Trade Commission (ITC) against BlackBerry. Unwired Planet stipulated to noninfringement and withdrew its complaint on the eve of trial, after the ITC issued a claim construction order under which Unwired Planet admitted that there was no infringement. In subsequent proceedings in the U.S. District Court for the District of Delaware, the district court entered the identical claim construction, and Unwired Planet again stipulated to judgment of noninfringement. The U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment of noninfringement.
  • Represented BlackBerry on intellectual property issues in connection with its $777 million investment in a consortium that acquired a substantial majority of the former Nortel Networks patent portfolio for $4.5 billion. The portfolio consisted of approximately 4,000 patent assets related to a broad array of networking, communications and internet technologies. The deal was one of the largest public sales of intellectual property assets in history and was the recipient of the 2012 International Financial Law Review “M&A Deal of the Year Award.”
  • Immersion Corp. v. Sony Computer Entertainment (N.D. Cal.). Represented Immersion Corporation, a leading developer of "haptic" technologies that allow people to interact with computers using their sense of touch, in a patent infringement lawsuit alleging that various PlayStation game products infringe two Immersion patents relating to computer-controlled vibrotactile technologies. In September 2004, after a five-week trial, the jury returned a verdict in favor of Immersion, finding all asserted patent claims valid and infringed and awarding $82 million in damages. In February 2007, after Immersion prevailed in a series of post-trial proceedings, Sony paid Immersion more than $150 million, which included Sony's satisfaction in full of the judgment, as well as payment of interest, compulsory license fee and future royalties. Also represented Immersion in patent litigation against Microsoft Corporation, which settled in July 2003.
  • Peer Communications v. eBay and Skype (E.D. Tex.). Represented defendants eBay and Skype in a patent infringement suit related to internet communications, including what is known as VoIP (voice over internet protocol). The plaintiff was a subsidiary of Acacia Research Corp. After claim construction, the district court entered judgment for eBay and Skype based on patent invalidity and dismissed the case with prejudice. The judgment was affirmed by the U.S. Court of Appeals for the Federal Circuit.
  • Net2Phone v. eBay and Skype (D.N.J.); eBay v. IDT and Net2Phone (W.D. Ark.). Represented eBay and Skype in several patent infringement lawsuits related to internet communications, including VoIP (voice over internet protocol) and calling card technology. Net2Phone first filed suit in New Jersey. eBay subsequently filed suit in Arkansas against Net2Phone and its parent IDT. Although filed two years later, eBay's case in Arkansas was scheduled for trial well before Net2Phone's case in New Jersey. Both cases settled successfully shortly before trial.
  • Avago Technologies Ltd. v. PixArt Imaging, Inc. (N.D. Cal.). Represented Avago Technologies in a patent infringement case involving optical navigation technology for optical computer mouse applications. The accused products were PixArt's CMOS optical mouse sensors. The case settled successfully for Avago, with PixArt agreeing to take a worldwide license to certain Avago intellectual property.

Honors & Awards

  • Recommended individual in litigation by IAM Patent 1000 (2019-2026)
  • Selected to the Southern California Super Lawyers list in the area of intellectual property litigation (2013-2022, 2024-2027)

  • Selected to the Lawdragon 500 Leading Litigators in America (2023–2027)

  • Selected to the Southern California Rising Stars list in the area of intellectual property litigation (2006-2011)

Publications

  • “The Myriad Reasons to Hit ‘Reset’ on Patent-Eligibility Jurisprudence,” 47 Loyola of Los Angeles Law Review 117 (2013)

Education

Loyola Law School (J.D., 2000), summa cum laude; Valedictorian

State University of New York at Buffalo (Ph.D., 1996)

Washington and Lee University (B.A., 1990), magna cum laude; Phi Beta Kappa

Admissions

  • California, 2001
  • U.S. District Court for the Central and Northern Districts of California
  • U.S. Court of Appeals for the Ninth and Federal Circuits

Clerkships

  • Hon. Diarmuid F. O'Scannlain, U.S. Court of Appeals for the Ninth Circuit
Jump to Page
Close

Irell & Manella LLP Cookie Preference Center

Your Privacy

When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use Cookies, please see our Privacy Policy.

Strictly Necessary Cookies

Always Active

Necessary cookies enable core functionality such as security, network management, and accessibility. These cookies may only be disabled by changing your browser settings, but this may affect how the website functions.

Functional Cookies

Always Active

Some functions of the site require remembering user choices, for example your cookie preference, or keyword search highlighting. These do not store any personal information.

Form Submissions

Always Active

When submitting your data, for example on a contact form or event registration, a cookie might be used to monitor the state of your submission across pages.

Performance Cookies

Performance cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.

Powered by Firmseek